Ixekizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL-17a |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number |
1143503-69-8  |
| ATC code | none |
| ChemSpider | none |
| Chemical data | |
| Formula | C6492H10012N1728O2028S46 |
| Molar mass | 146.2 kg/mol |
 (what is this?) (verify) | |
Ixekizumab is a humanized monoclonal antibody for the treatment of autoimmune diseases.[1] It was approved by the FDA on March 22, 2016 for the treatment of psoriasis, under the trade name Taltz.[2] Clinical trials included a Phase II clinical trial of patients with moderate to severe psoriasis,[3] and a Phase III open-label trial as of November 2013.[4]
Ixekizumab was developed by Eli Lilly and Co.
Mechanism of action
Ixekizumab binds to interleukin 17 and blocks its action. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which also binds to the interleukin-17 receptor.[3]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab" (PDF). American Medical Association.
- ↑ "FDA approves new psiorasis drug Taltz". Food and Drug Administration.
- 1 2 "Neue Antikörper in der Pipeline". Pharmazeutische Zeitung (in German) (12). 2012.
- ↑ Clinical trial number NCT01624233 for "A Study in Japanese Participants With Moderate-to-Severe Psoriasis" at ClinicalTrials.gov
This article is issued from Wikipedia - version of the Wednesday, March 23, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.